Selpercatinib: all 30 studies that test it

Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in IndiaNot yet recruitingNCT07822880Phase 4
• Feasibility Study for Repurposing RET InhibitorsNot yet recruitingNCT07146893Early Phase 1
• Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingNCT07010393Phase 4
• Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TCRecruitingNCT05668962Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy ParticipantsCompletedNCT05906836Phase 1Results posted
• A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male ParticipantsCompletedNCT05630287Phase 1Results posted
• A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy ParticipantsCompletedNCT05630274Phase 1Results posted
• A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy ParticipantsCompletedNCT05469113Phase 1Results posted
• A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal FunctionCompletedNCT05469100Phase 1Results posted
• A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy ParticipantsCompletedNCT05468164Phase 1Results posted
• A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy ParticipantsCompletedNCT05436912Phase 1Results posted
• A Study of Selpercatinib (LY3527723) in Healthy ParticipantsCompletedNCT05338515Phase 1Results posted
• A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy ParticipantsCompletedNCT05338476Phase 1Results posted
• A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy ParticipantsCompletedNCT05324124Phase 1Results posted
• A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy ParticipantsCompletedNCT05136404Phase 1Results posted
• A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy ParticipantsCompletedNCT05089019Phase 1Results posted
• A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy ParticipantsCompletedNCT04782076Phase 1Results posted
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 2Results posted
• A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationActive, not recruitingNCT04280081Phase 2Results posted
• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerActive, not recruitingNCT04211337Phase 3Results posted
• A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerActive, not recruitingNCT04194944Phase 3Results posted
• A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung CancerWithdrawnNCT05364645Phase 2
• A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04819100Phase 3
• Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid CancerActive, not recruitingNCT04759911Phase 2
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)Active, not recruitingNCT04268550Phase 2

← Selpercatinib overview